Caution - Investigational Drug; Limited by United States Law to Investigational use only.
Caution - Investigational Drug; Limited by United States Law to Investigational use only.
 
 
1
2
3

Welcome

Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development

Acute heart failure

AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation.

Ularitide

Ularitide is an advanced natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF).

 

Welcome to Cardiorentis AG

Welcome to Cardiorentis AG

Cardiorentis AG is a privately owned pharmaceutical company based in Zug, Switzerland. 

Focused, fast moving, flexible, with patients at its heart, Cardiorentis is committed to introducing the first therapy with proven outcome benefits  for patients with acute heart failure and developing innovative medicines for diseases of high unmet medical need.

Latest News

  • 17-09-2014

    Press release

    Cardiorentis Announces €45 Million Financing with HealthCare Royalty Partners to Fund Ularitide Registration Program in Acute Heart Failure

    Read more information

  • 16-09-2014

    Join Us

    At Acute Cardiovascular Care 2014 (ACC2014) 18th – 20th October 2014 in Geneva.

    Visit our Stand E200 to find out the latest  on the TRUE-AHF trial.